Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;29(4):487-493.
doi: 10.1111/jns.12662. Epub 2024 Oct 10.

Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study

T Rehbein  1 , J Purks  1 , N Dilek  1 , S Behrens-Spraggins  1 , J E Sowden  1 , K J Eichinger  1 ; ACT‐CMT Study Group; J Burns  2 , D Pareyson  3 , S S Scherer  4 , M M Reilly  5 , M E Shy  6 , M P McDermott  1   7   8 , C R Heatwole  1   8 , D N Herrmann  1
Collaborators, Affiliations

Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study

T Rehbein et al. J Peripher Nerv Syst. 2024 Dec.

Abstract

Background and aims: The Charcot-Marie-Tooth Disease Health Index (CMT-HI) is a disease-specific, patient-reported disease burden measure. As part of an international clinical trial readiness study, individuals with CMT1A (ages 18-75 years) underwent clinical outcome assessments (COAs), including the CMT-HI, to capture their longitudinal perspective on the disease burden.

Methods: Two hundred and fifteen participants underwent serial COAs including the CMT-HI, CMT Functional Outcome Measure (CMT-FOM), CMT Neuropathy Score (CMTNSv2R), and CMT Exam Score (CMTES/CMTES-R). Correlations between the total and subscale scores for the CMT-HI and other COAs were determined. Changes in the CMT-HI scores over 12 months were assessed using paired t-tests. The minimum clinically important difference (MCID) for the CMT-HI and its subscales were calculated by anchoring to a participant global impression of change scale.

Results: At baseline, CMT1A participants were 44.5 ± 15 years old (range: 18-75) and 58% were women. The mean CMT-HI was 25.7 ± 18.8 (range: 0-91.9; 100 reflecting maximal disease burden). The CMT-HI correlated with the CMT-FOM (r = .54, p < .0001), CMTNSv2R (r = .48, p < .0001), and CMTES/CMTES-R (r = .52/r = .54, p < .0001). Disease burden was greater in women than in men (CMT-HI 29.1 ± 19.1 vs. 21.2 ± 17.3, p = .001). Over 12 months, there was a nonsignificant mean increase in CMT-HI of 0.40 ± 10.0 (n = 189, p = .89). The MCID for the CMT-HI total score was 3.8 points (95% CI: 1.7-5.9).

Discussion: Patient-reported disease burden in CMT1A as measured by the CMT-HI is associated with measures of neurologic impairment and physical functioning. Women reported a higher disease burden than men. These data will inform the design of clinical trials in CMT1A.

Keywords: CMT; CMT HI; CMT Health Index; CMT1A; Charcot–Marie–tooth disease; MCID; clinical trial design; patient‐reported outcomes; quality of life; sex differences.

PubMed Disclaimer

References

    1. Morena J, Gupta A, Hoyle JC. Charcot-Marie-Tooth: From Molecules to Therapy. Int J Mol Sci. Jul 12 2019;20(14)doi:10.3390/ijms20143419 - DOI - PMC - PubMed
    1. Johnson NE, Heatwole CR, Ferguson M, Sowden JE, Jeanat S, Herrmann DN. Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A. J Clin Neuromuscul Dis. Sep 2013;15(1):19–23. doi:10.1097/CND.0b013e31829e22e3 - DOI - PMC - PubMed
    1. Karadima G, Floroskufi P, Koutsis G, Vassilopoulos D, Panas M. Mutational analysis of PMP22, GJB1 and MPZ in Greek Charcot-Marie-Tooth type 1 neuropathy patients. Clin Genet. Nov 2011;80(5):497–9. doi:10.1111/j.1399-0004.2011.01657.x - DOI - PubMed
    1. Braathen GJ. Genetic epidemiology of Charcot-Marie-Tooth disease. Acta Neurol Scand Suppl. 2012;(193):iv–22. doi:10.1111/ane.12013 - DOI - PubMed
    1. Theadom A, Roxburgh R, MacAulay E, et al. Prevalence of Charcot-Marie-Tooth disease across the lifespan: a population-based epidemiological study. BMJ Open. Jun 14 2019;9(6):e029240. doi:10.1136/bmjopen-2019-029240 - DOI - PMC - PubMed